Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach

Journal of Medicinal Chemistry

Volumn 51, Issue 12, 2008, Pages 3367-3377

  Gundla, Rambabu ^a   Kazemi, Roza ^a   Sanam, Ramadevi ^b   Muttineni, Ravikumar ^b   Sarma, Jagarlapudi A R P ^b   Dayam, Raveendra ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GVK BIOSCIENCES PVT LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DATA BASE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; PHARMACOPHORE; PHYSICAL CHEMISTRY; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CATALYTIC DOMAIN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERAZINES; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2; SMALL MOLECULE LIBRARIES;

EID: 45749146280     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7013875     Document Type: Article

References (55)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103 (2), 211-225.
2. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31 (6), 637-643.
3. Guy, P. M.; Platko, J. V.; Cantley, L. C.; Cerione, R. A.; Carraway, K. L., III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (17), 8132-8136.
4. Jones, J. T.; Akita, R. W.; Sliwkowski, M. X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 1999, 447 (2-3), 227-231.
5. Cho, H. S.; Mason, K.; Ramyar, K. X.; Stanley, A. M.; Gabelli, S. B.; Denney, D. W.; Leahy, D. J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421 (6924), 756-760.
6. Garrett, T. P.; McKern, N. M.; Lou, M.; Elleman, T. C.; Adams, T. E.; Lovrecz, G. O.; Kofler, M.; Jorissen, R. N.; Nice, E. C.; Burgess, A. W.; Ward, C. W. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 2003, 11 (2), 495-505.
7. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5 (5), 341-354.
8. Moy, B.; Kirkpatrick, P.; Kar, S.; Goss, P. Lapatinib. Nat. Rev. Drug Discovery 2007, 6 (6), 431-432.
9. Reid, A.; Vidal, L.; Shaw, H.; de Bono, J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer 2007, 43 (3), 481-489.
10. Spector, N.; Xia, W.; El-Hariry, I.; Yarden, Y.; Bacus, S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res. 2007, 9 (2), 205.
11. Moro, S.; Bacilieri, M.; Deflorian, F. Combining ligand-based and structure-based drug design in the virtual screening arena. Exp. Opin. Drug Discovery 2007, 2 (1), 37-49.
12. GOLD 1.2; CCDC: Cambridge, UK, 2002.
13. Aparna, V.; Rambabu, G.; Panigrahi, S. K.; Sarma, J. A.; Desiraju, G. R. Virtual screening of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions. J. Chem. Inf. Model. 2005, 45 (3), 725-738.
14. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 2006, 49 (21), 6177-6196.
15. Zsoldos, Z.; Reid, D.; Simon, A.; Sadjad, S. B.; Johnson, A. P. eHiTS: A new fast, exhaustive flexible ligand docking system. J. Mol. Graph. Model. 2007, 26 (1), 198-212.
16. Fantin, V. R.; Berardi, M. J.; Babbe, H.; Michelman, M. V.; Manning, C. M.; Leder, P. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. Cancer Res. 2005, 65 (15), 6891-6900.
17. Gril, B.; Vidal, M.; Assayag, F.; Poupon, M. F.; Liu, W. Q.; Garbay, C. Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel. Int. J. Cancer 2007, 121 (2), 407-415.
18. Jin, Y.; Li, H. Y.; Lin, L. P.; Tan, J.; Ding, J.; Luo, X.; Long, Y. Q. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8- nitroquinazolines as EGFR signaling-targeted inhibitors. Bioorg. Med. Chem. 2005, 13 (19), 5613-5622.
19. Zhang, N.; Wu, B.; Wissner, A.; Powell, D. W.; Rabindran, S. K.; Kohler, C.; Boschelli, F. 4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors. Bioorg. Med. Chem. Lett. 2002, 12 (3), 423-425.
20. Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y. F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3- carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 2005, 48 (4), 1107-1131.
21. Hudson, A. T.; Vile, S.; Barraclough, P.; Franzmann, K. W.; McKeown, S. C.; Page, M. J., Preparation of quinoline and quinazoline protein tyrosine kinase inhibitors. WO 9609294 A1, 1996.
22. Feld, R.; Sridhar, S. S.; Shepherd, F. A.; Mackay, J. A.; Evans, W. K. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J. Thorac. Oncol. 2006, 1 (4), 367-376.
23. Kinase-Database, Informatics; GVK Biosciences Pvt. Ltd.: Balanagar, Hyderabad, India.
24. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J. Med. Chem. 1991, 34 (6), 1896-1907.
25. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 1997, 40 (7), 1130-1135.
26. Hugh, R. B.; Grant, J. K. Preparation of (anilino)quinazoline derivatives as antiproliferative agents. WO 2004093880 A1, 2004.
27. Stuart, G. C.; Clive, M. C.; Barry, S. G.; Jane, K. S. Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors. WO 9802434 A1, 1998.
28. Mien-Chie, H.; Lisha, Z. Emodin and related compounds for sensitization of HER2/neu over-expressing cancer cells to chemotherapeutic drugs. WO 9727848 A1, 1997.
29. Neal, R.; Scott, D. K.; Samuel, J. D.; Furzhong, F. Z.; Laura, S.; Ouathek, O. Methods and compositions using bifunctional hsp-binding derivatives for degradation and/or inhibition of HER-family tyrosine kinases and treatment of cancer. WO 2000061578 A1, 2000.
30. Hui, C.; Aviv, G.; Peter, K. H.; Elaina, M.; Laura, K. S.; Jianming, T.; Cho, P. T. Methods and compositions using receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders, and inhibitor preparation. U.S. Patent 5789427 A, 1998.
31. Akihiro, T.; Takenori, H.; Etsuya, M. Preparation of 2-styryl-4- (phenoxymethyl)oxazole derivatives as tyrosine kinase inhibitors. WO 2001077107 A1, 2001.
32. Yu, M.; Etsuya, M. Preparation of aralkylazoles as tyrosine kinase inhibitors useful as antitumor agents. WO 9803505 A2, 1998.
33. Chen, H.; Gazit, A.; Levitzki, A.; Hirth, K. P.; Mann, E.; Shawver, K. L.; Tsai, J.; Tang, P. C. Methods and compositions for inhibiting cell proliferative disorders. U.S. Patent 20020068687 A1, 2002.
34. Peter, H. K.; Pruess, S. D.; Elaina, M.; Kay, S. L.; Gyorgi, K.; Istvan, S.; Tamas, B.; Janis, H.; Laszlo, O.; Alex, L.; Aviv, G.; Axel, U.; Reiner, L.; Fairooz, F. K.; Dennis, S.; Cho, T. P. Treatment of platelet derived growth factor-related disorders such as cancers. U.S. Patent 5958959 A, 1999.
35. Ronghui, L.; Peter, J. C.; Steven, W.; Shenlin, H.; Stuart, E.; Robert, G.; Steve, M. Preparation of 1,2,4-triazole-3,5-diamine derivatives as kinase inhibitors. WO 2002057240 A1, 2002.
36. Stuart, C. G.; Clive, C. M.; Barry, G. S.; Jane, S. K. Preparation of bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. WO 9802437 A1, 1998.
37. Stuart, C. G.; Clive, C. M.; Karl, M. S.; Sadie, V.; John, P. M.; Thomas, H. A.; Paul, B.; Witold, F. K. Preparation of heterocyclyl-substituted quinazolines as protein tyrosine kinase inhibitors. WO 9703069 A1, 1997.
38. Garcia-Echeverria, C.; Fabbro, D. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. Mini Rev. Med. Chem. 2004, 4 (3), 273-283.
39. Bridges, A. J. Chemical inhibitors of protein kinases. Chem. Rev. 2001, 101 (8), 2541-2572.
40. Revesz, L.; Blum, E.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 2004, 14 (13), 3595-3599.
41. Gaul, M. D.; Guo, Y.; Affleck, K.; Cockerill, G. S.; Gilmer, T. M.; Griffin, R. J.; Guntrip, S.; Keith, B. R.; Knight, W. B.; Mullin, R. J.; Murray, D. M.; Rusnak, D. W.; Smith, K.; Tadepalli, S.; Wood, E. R.; Lackey, K. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. Bioorg. Med. Chem. Lett. 2003, 13 (4), 637-640.
42. Borzilleri, R. M.; Zheng, X.; Qian, L.; Ellis, C.; Cai, Z. W.; Wautlet, B. S.; Mortillo, S.; Jeyaseelan, R. Sr.; Kukral, D. W.; Fura, A.; Kamath, A.; Vyas, V.; Tokarski, J. S.; Barrish, J. C.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Bhide, R. S. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4] triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J. Med. Chem. 2005, 48 (12), 3991-4008.
43. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; Peters, U.; Davies, P.; Chiosis, G. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48 (8), 2892-2905.
44. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y. F.; Greenberger, L. M.; Tsou, H. R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquino-line-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003, 46 (1), 49-63.
45. Smaill, J. B.; Showalter, H. D.; Zhou, H.; Bridges, A. J.; McNamara, D. J.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Vincent, P. W.; Roberts, B. J.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. J. Med. Chem. 2001, 44 (3), 429-440.
46. Tsou, H. R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y. F.; Wissner, A. 6-Substituted-4-(3- bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 2001, 44 (17), 2719-2734.
47. Wells, G.; Seaton, A.; Stevens, M. F. Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. J. Med. Chem. 2000, 43 (8), 1550-1562.
48. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43 (7), 1380-1397.
49. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 1998, 41 (14), 2588-2603.
50. Cerius2 4.11; Accelrys Inc.:San Diego, CA, 2005.
51. Catalyst 4.11; Accelrys Inc.:San Diego, CA, 2005.
52. Smellient, A. T., S. L.; Towbin, P. Polings-promoting conformational variation. J. Comput. Chem. 1995, 16, 171-187.
53. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277 (48), 46265-46272.
54. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64 (18), 6652-6659.
55. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 2007, 50 (3), 409-424.